Published in:
01-12-2007 | Erratum
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
Published in: Diabetologia | Issue 12/2007
Login to get accessExcerpt
An incorrect conversion factor was used by the authors resulting in values given in g/l being ten times higher than they should have been. The corrected sections of Tables 1, 2, 3, 4 are reproduced below.
Table 1
Basic lipid panel and lipid transfer protein activities before and during Fenofibrate treatment
|
|
Baseline
|
Fifth year
|
p value
|
|
|---|---|---|---|---|
|
|
Difference of change between the groups
|
|||
|
apoB (g/l)
|
||||
|
Placebo
|
0.96 (0.82–1.07)
|
1.00 (0.89–1.17)
|
||
|
Fenofibrate
|
1.00 (0.91–1.12)
|
0.84 (0.70–0.98)
|
−24.7 (−18.4, −31.0)
|
<0.001
|
Table 2
Triacylglycerol, cholesterol and particle mass concentration of VLDL 1, VLDL 2 and IDL in type 2 diabetic patients
|
|
Baseline
|
Second year
|
Fifth year
|
p value
|
||
|---|---|---|---|---|---|---|
|
|
Difference of change between the groups
|
|
Difference of change between the groups
|
|||
|
VLDL1 particle mass (g/l)
|
||||||
|
Placebo
|
0.88 (0.50–1.44)
|
0.85 (0.51–1.20)
|
−39.4 (−25.6, −53.6)
|
0.81 (0.51–1.26)
|
−43.5 (−29.5, −59.4)
|
<0.001
|
|
Fenofibrate
|
0.85 (0.49–1.42)
|
0.47 (0.25–0.73)
|
0.38 (0.22–0.85)
|
|||
|
VLDL2 particle mass (g/l)
|
||||||
|
Placebo
|
0.60 (0.42–0.78)
|
0.60 (0.41–0.80)
|
−32.1 (−19.2, −44.8)
|
0.54 (0.42–0.80)
|
−32.5 (−20.0, −45.3)
|
<0.001
|
|
Fenofibrate
|
0.58 (0.39–0.78)
|
0.36 (0.24–0.52)
|
0.38 (0.23–0.60)
|
|||
|
IDL particle mass (g/l)
|
||||||
|
Placebo
|
0.39 (0.30–0.50)
|
0.39 (0.30–0.46)
|
−5.7 (2.6, −14.5)
|
0.40 (0.32–0.47)
|
−12.0 (−2.0, −21.5)
|
0.019
|
|
Fenofibrate
|
0.38 (0.30–0.49)
|
0.33 (0.26–0.43)
|
0.32 (0.25–0.46)
|
|||
Table 3
Cholesterol concentration, particle mass of HDL2 and HDL3, and concentrations of apolipoproteins and apoA-containing lipoproteins in type 2 diabetic patients
|
|
Baseline
|
Second year
|
Fifth year
|
p value
|
||
|---|---|---|---|---|---|---|
|
|
Difference of change between the groups
|
|
Difference of change between the groups
|
|||
|
HDL2 Particle mass (g/l)
|
||||||
|
Placebo
|
0.89 (0.72–1.20)
|
0.89 (0.71–1.22)
|
−20.0 (−12.5, −28.0)
|
0.97 (0.71–1.41)
|
−23.1 (−13.6, −32.2)
|
<0.001
|
|
Fenofibrate
|
0.95 (0.72–1.29)
|
0.73 (0.55–0.96)
|
0.76 (0.61–1.02)
|
|||
|
HDL3 Particle mass (g/l)
|
||||||
|
Placebo
|
2.13 (1.93–2.35)
|
2.32 (2.16–2.58)
|
7.7 (2.8, 12.8)
|
2.41 (2.26–2.65)
|
12.5 (7.2, 17.9)
|
<0.001
|
|
Fenofibrate
|
2.14 (1.92–2.28)
|
2.50 (2.24–2.71)
|
2.69 (2.44–2.94)
|
|||
|
apoA-I (g/l)
|
||||||
|
Placebo
|
1.34 (1.21–1.51)
|
1.32 (1.21–1.48)
|
−0.7 (−4.2, 2.8)
|
1.34 (1.23–1.51)
|
−0.5 (−3.9, 3.7)
|
NS
|
|
Fenofibrate
|
1.36 (1.25–1.45)
|
1.32 (1.21–1.46)
|
1.34 (1.25–1.50)
|
|||
|
apoA-II (g/l)
|
||||||
|
Placebo
|
0.34 (0.31–0.37)
|
0.34 (0.31–0.39)
|
22.9 (18.2, 28.1)
|
0.31 (0.27–0.37)
|
26.9 (19.6, 34.4)
|
<0.001
|
|
Fenofibrate
|
0.33 (0.30–0.37)
|
0.40 (0.37–0.46)
|
0.42 (0.35–0.48)
|
|||
|
LpA-I (g/l)
|
||||||
|
Placebo
|
0.48 (0.41–0.61)
|
0.46 (0.37–0.59)
|
−20.4 (−13.4, −27.5)
|
0.48 (0.39–0.65)
|
−21.1 (−12.7, −30.0)
|
<0.001
|
|
Fenofibrate
|
0.49 (0.41–0.59)
|
0.35 (0.30–0.42)
|
0.39 (0.31–0.45)
|
|||
|
LpAI-AII (g/l)
|
||||||
|
Placebo
|
0.83 (0.75–0.90)
|
0.86 (0.78–0.95)
|
10.6 (5.5, 16.0)
|
0.83 (0.77–0.96)
|
11.5 (5.3, 17.3)
|
<0.001
|
|
Fenofibrate
|
0.83 (0.77–0.92)
|
0.96 (0.89–1.06)
|
0.97 (0.88–1.07)
|
|||
Table 4
The baseline HDL panel in the groups of low and high homocysteine levels
|
|
Lowest quartile (n = 56)
|
Highest quartile (n = 60)
|
p value
|
|---|---|---|---|
|
apoA-I (g/l)
|
1.37 (1.21–1.55)
|
1.29 (1.19–1.43)
|
0.131
|
|
apoA-II (g/l)
|
0.34 (0.30–0.38)
|
0.32 (0.31–0.36)
|
0.040
|
|
LpA-I (g/l)
|
0.51 (0.41–0.65)
|
0.48 (0.41–0.61)
|
0.904
|
|
LpAI-AII (g/l)
|
0.85 (0.79–0.93)
|
0.81 (0.74–0.87)
|
0.017
|